Contents

Talk:Alexion Pharmaceuticals

This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Companies High‑importance This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles High This article has been rated as High-importance on the project's importance scale. WikiProject Companies To-do: Here are some tasks awaiting attention: Article requests : Wikipedia:Requested articles/Business and economics/Companies Assess : Category:Unassessed company articles Copyedit : Category:Company articles needing attention Infobox : Category:Company articles needing infoboxes Maintain : Portal:Companies Stubs : Help expand stub articles located at Category:Company stubs Other : Tag company articles with the {{portal|Companies}} template Tag company talk pages with the {{WikiProject Companies}} project banner Answer requests for comments Pharmacology Low‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles Low This article has been rated as Low-importance on the project's importance scale. Connecticut Low‑importance This article is within the scope of WikiProject Connecticut, a collaborative effort to improve the coverage of Connecticut on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.ConnecticutWikipedia:WikiProject ConnecticutTemplate:WikiProject ConnecticutConnecticut articles Low This article has been rated as Low-importance on the project's importance scale.

Donating Soliris in Germany[edit]

...in a rare expression of good will, and hoping for more media attention <g> 46.138.95.18 (talk) 06:36, 6 November 2011 (UTC)[reply]

Products: Soliris, Kanuma, Strensiq^[1]
Revenue: US$ 2.604 bil (2015)^[2]
Operating Income: US$ 536.671 mil (2015)^[3]
Net income: US$ 144.385 mil (2015)^[4]
Total assets: US$ 13.133230 bil (2015)^[5]
Total equity: US$ 8.258616 bil (2015)^[6]
Number of employees: 3,000 (2015)^[7]
Website: www.alexion.com

It also employes about 3,000 people worldwide.^[8]

Acquisitions Synageva's main drug, Kanuma, received approval in the United Stations on December 8, 2015 and European approval on September 1, 2015.^[9]

The Synageva acquisiton was completed on June 22, 2015.^[10]

Kanuma Kanuma is also approved in the European Union^[11] and Japan^[12].

KateDietz (talk) 20:07, 3 November 2016 (UTC)[reply]